Dr. Peter S. Nelson

powered by
COS Expertise®
Fred Hutchinson Cancer Research Center
Human Biology Division
Program in Prostate Cancer Research
Member
University of Washington
School of Medicine
Medicine
Oncology
Professor
University of Washington
School of Medicine
Genome Sciences and Pathology
Adjunct
Professional Headshot of Peter S. Nelson

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N., D4-100
P.O. Box 19024
Seattle, Washington 98109-1024
United States

Contact Information

pnelson@fhcrc.org

Qualifications

M.D., University of Kansas, Medicine, 1986.
B.A., University of Kansas, Chemistry/Biology/Biochemistry, 1982.

Expertise and Research Interests

The focus of current work in the Nelson lab involves efforts to understand the process of prostate carcinogenesis with an aim toward developing diagnostic, prognostic, and therapeutic strategies.

The Major Projects are:

1. Molecular Analysis of Therapies for Early and Late Stage Prostate Carcinoma. These investigations aim to determine molecular features that associate with response and resistance mechanisms to cytotoxic chemotherapy and pathway-targeted agents. Several clinical (translational) trials are underway including a studies incorporating neoadjuvant therapies followed by radical prostatectomy. Tissue samples are acquired pre- and post-therapy and molecular correlates of direct drug effects are identified to define signatures: (a) predictive of therapeutic response and (b) predictive of disease outcome (relapse).

2. Characterization of the Prostate Androgen-Response Program. A major focus of the lab has been the identification of down-stream ''effector'' genes that are responsible for cellular events (e.g. proliferation) after androgen receptor (AR) activation. We have identified >170 genes that are regulated by androgens in the prostate. Of these, many have expression profiles restricted to the prostate. Systematic studies involving overexpression and down-regulation of these genes is in progress to determine the cellular function with the aim of identifying those genes involved in proliferation, anti-apoptosis, and differentiation. Genes with prostate-restricted expression may serve as therapeutic targets.

3. Analysis of Prostate Serine Protease Function in Metastatic Prostate Carcinoma. Prostate cancer has a high prediliction for metastasizing to bone, and often produces a ''blastic'' bone response. We hypothesize that the expression or production of prostate proteases in ectopic sites (such as bone), contribute to this disease process. The prostate produces several proteases in a highly tissue-specific fashion including several novel proteases identified in our laboratory. Current studies are designed to characterize the substrate specificities of these proteases in order to determine if they may play a role in modulating carcinogenesis (invasion/metastasis) and serve as drug targets. We are also characterizing the function of several proteases through the use of transgenic mice.

4. Determining the role of aging and cellular senescence in prostate carcinogenesis. A new direction involves studies of aging-related changes in the prostate. This work represents a logical extension of studies attempting to understand the dramatic increase in prostate cancer incidence with advanced age. We have shown that senescent prostate stromal cells develop a secretory phenotype with the potential to influence the growth and survival of adjacent epithelium. We are now extending this work to understand aging related influences in other constituents of the tumor microenvironment and determine if androgens influence senescence and aging-related paracrine effects.

5. Normal Variation. This work evolved from large-scale analyses of transcript levels in benign tissues where we found that a substantial number of genes exhibit wide fluctuations in expression levels within genetically-identical individuals. We have shown that variability in gene expression within genetically identical individuals exceeds the genome-encoded variability across different genetic backgrounds, suggesting a mechanism for maintaining variation that could contribute to natural selection. Current work is focused on determining the role of normal variation in dictating cancer phenotypes.

Keywords

COS Keywords:

Biochemistry, Bioinformatics, Biotechnology, Cancer Or Carcinogenesis, Chemical Sciences, Gene Expression, Genomics, Internal Medicine, Metastasis, Oncology, Pathology, Prostate Cancer.

Honors and Awards

2001, Scholar Award, Damon Runyon
1998, Career Development Award, NIH
1990, Chief Resident, University of Kansas, Medicine
1989, Resident Excellence, Roy Edwards Jr. Award, University of Kansas
1981, NSF Research Award in Biochemistry, NSF, University of Kansas

Previous Positions

1993-1996, Fellowship, University of Washington, Fred Hutchinson Cancer Center, Medical Oncology
1990-1992, Biotechnology Fellowship, National Cancer Institute
1989-1990, Chief Resident, University of Kansas, School of Medicine - KUMC
1986-1989, Intern/Resident, University of Kansas, School of Medicine - KUMC

Publications

  • Marks LS, Mostaghel EA, Nelson PS (Aug 2008) Prostate tissue androgens: history and current clinical relevance., Urology, 72 (2), 247-54 Abstract
  • Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS, Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH, Ellis WJ, True LD, Young JM, Hsu L, Trask BJ, Vessella RL (Jul 2008) Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients., Cancer research, 68 (14), 5599-608 Abstract
  • Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (Jul 2008) Circulating microRNAs as stable blood-based markers for cancer detection., Proceedings of the National Academy of Sciences of the United States of America, 105 (30), 10513-8 Abstract
  • Lucas JM, True L, Hawley S, Matsumura M, Morrissey C, Vessella R, Nelson PS (Jun 2008) The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma., The Journal of pathology, 215 (2), 118-25 Abstract
  • Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS (Jun 2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth., Cancer research, 68 (11), 4447-54 Abstract
  • Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA (Jun 2008) Association of megalin genetic polymorphisms with prostate cancer risk and prognosis., Clinical cancer research : an official journal of the American Association for Cancer Research, 14 (12), 3823-31 Abstract
  • Tischkowitz MD, Yilmaz A, Chen LQ, Karyadi DM, Novak D, Kirchhoff T, Hamel N, Tavtigian SV, Kolb S, Bismar TA, Aloyz R, Nelson PS, Hood L, Narod SA, White KA, Ostrander EA, Isaacs WB, Offit K, Cooney KA, Stanford JL, Foulkes WD (Jun 2008) Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer., Cancer letters Abstract
  • Pritchard CC, Nelson PS (May 2008) Gene expression profiling in the developing prostate., Differentiation; research in biological diversity Abstract
  • Mostaghel EA, Nelson PS (Apr 2008) Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications., Best practice & research. Clinical endocrinology & metabolism, 22 (2), 243-58 Abstract
  • Lin B, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS, Hood L, Kalland KH, Akslen LA (Mar 2008) WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence., Clinical cancer research : an official journal of the American Association for Cancer Research, 14 (5), 1397-406 Abstract
  • Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V (Feb 2008) A causal role for ERG in neoplastic transformation of prostate epithelium., Proceedings of the National Academy of Sciences of the United States of America, 105 (6), 2105-10 Abstract
  • Dean JP, Nelson PS (Jan 2008) Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis., British journal of cancer, 98 (2), 245-9 Abstract
  • Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, Liu AY (2008) Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate., BMC genomics, 9, 246 Abstract
  • Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey E, Lange PH, Higano CS, Vessella RL (2008) Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases., Clinical & experimental metastasis, 25 (4), 377-88 Abstract
  • Xu C, Graf LF, Fazli L, Coleman IM, Mauldin DE, Li D, Nelson PS, Gleave M, Plymate SR, Cox ME, Torok-Storb BJ, Knudsen BS (Nov 2007) Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression., The Prostate, 67 (15), 1621-9 Abstract
  • Datta MW, True LD, Nelson PS, Amin MB (Nov 2007) The role of tissue microarrays in prostate cancer biomarker discovery., Advances in anatomic pathology, 14 (6), 408-18 Abstract
  • Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Nelson PS (Oct 2007) Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15., Clinical cancer research : an official journal of the American Association for Cancer Research, 13 (19), 5825-33 Abstract
  • Lin DW, Neuhouser ML, Schenk JM, Coleman IM, Hawley S, Gifford D, Hung H, Knudsen BS, Nelson PS, Kristal AR (Oct 2007) Low-fat, low-glycemic load diet and gene expression in human prostate epithelium: a feasibility study of using cDNA microarrays to assess the response to dietary intervention in target tissues., Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 16 (10), 2150-4 Abstract
  • Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM (Sep 2007) Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer., Cancer, 110 (5), 996-1002 Abstract
  • He Y, Franco OE, Jiang M, Williams K, Love HD, Coleman IM, Nelson PS, Hayward SW (Sep 2007) Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression., Cancer research, 67 (17), 8188-97 Abstract
  • Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS (May 2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer., Cancer research, 67 (10), 5033-41 Abstract
  • Bianchi-Frias D, Pritchard C, Mecham BH, Coleman IM, Nelson PS (2007) Genetic background influences murine prostate gene expression: implications for cancer phenotypes., Genome biology, 8 (6), R117 Abstract
  • Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM. ( (2007) Diethylstilbestrol and docetaxel: a phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer, Cancer, In Press
  • Bianchi-Frias D, Pritchard C, Mecham BH, Coleman IM, Nelson PS. (2007) Genetic background influences murine prostate gene expression: implications for cancer phenotypes., Genome Biology, 8 (6), R117
  • Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer., Cancer Research, 67 (10), 5033-41
  • Marks LS, Mazer NA, Mostaghel EA, Hess DL, Dorey FJ, Bostwick DG, Epstein JI, Partin AW, Veltri RW, Makarov D, Macairan ML, and Nelson PS (2006) Effect of Testosterone Replacement Therapy on Prostate Tissue in Men with Late-Onset Hypogonadism: A Randomized Controlled Trial., Journal of the American Medical Association, 296 (19), 2351-2361
  • Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, Plymate SR (2006) Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors, Clin Cancer Res, 12 (20), 6153-60
  • Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, Corey (2006) Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes, Neoplasia, 8 (10), 862-78
  • Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ (2006) Persistent intraprostatic androgen concentrations after medical castration in healthy men, J Clin Endocrinol Metab, 91 (10), 3850-6
  • True L, Coleman I, Gifford D, Hawley, S, Huang A, Gifford D, Coleman R, Beer T, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, and Nelson PS (2006) A Molecular Correlate to the Gleason Grading System for Prostate Cancer., Proc Natl Acad Sci USA, 103 (29), 10991-6
  • Pritchard C, Coil D, Hsu L, and Nelson PS (2006) The Contributions of Normal Variation and Genetic Background to Mammalian Gene Expression, Genome Biology, 7 (3), R26
  • Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR (2006) Interaction of IGF signaling and the androgen receptor in prostate cancer progression., J Cell Biochem
  • Lin DW, Coleman IM, Hawley S, Dumpit R, Gifford D, Kezele P, Hung H, Knudsen BS, Kristal A, and Nelson PS (2006) The influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis., Journal of Clinical Oncology, 24 (23), 3763-70
  • Bavik C, Coleman I, Dean J, Knudsen B, and Nelson PS (2006) The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms., Cancer Research, 55 (2), 794-802
  • Kim TS, Heinlein C, Hackman R, and Nelson PS (2006) Phenotypic Analysis of Mice Lacking the Tmprss2 protease, Mol Cell Biol, 26 (3), 965-75
  • Khodavirdi AC, Song S, Yang S, Wu H, Pritchard C, Nelson PS, and Roy-Burman P (2006) Increased Expression of Osteopontin Contributes to the Progression of Prostate Cancer., Cancer Research, 66 (2), 883-8
  • Montgomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R, Stahl WL (Oct 2005) Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells, The Prostate, 65 (2), 141-50
  • Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE (Jul 2005) Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate, The American Journal of Pathology, 167 (1), 255-66
  • Fraser MM, Watson PM, Fraig MM, Kelley JR, Nelson PS, Boylan AM, Cole DJ, Watson DK (Jul 2005) CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability, Cancer Research, 65 (14), 6228-36
  • Bonham M, Posakony J, Coleman I, Montgomery B, Simon J, Nelson PS (May 2005) Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma, Clinical Cancer Research : an Official Journal of the American Association for Cancer Research., 11 (10), 3905-14
  • Belyaeva OV, Korkina OV, Stetsenko AV, Kim T, Nelson PS, Kedishvili NY (May 2005) Biochemical properties of purified human retinol dehydrogenase 12 (RDH12): catalytic efficiency toward retinoids and C9 aldehydes and effects of cellular retinol-binding protein type I (CRBPI) and cellular retinaldehyde-binding protein, Biochemistry, 44 (18), 7035-47
  • Moore S, Knudsen B, True LD, Hawley S, Etzioni R, Wade C, Gifford D, Coleman I, Nelson PS (Apr 2005) Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma, International Journal of Cancer. Journal International Du Cancer, 114 (4), 563-71
  • Kim TS, Maeda A, Maeda T, Heinlein C, Kedishvili N, Palczewski K, Nelson PS (Mar 2005) Delayed dark adaptation in 11-cis-retinol dehydrogenase-deficient mice: a role of RDH11 in visual processes in vivo, The Journal of Biological Chemistry, 280 (10), 8694-704
  • Matsumura M, Bhatt AS, Andress D, Clegg N, Takayama TK, Craik CS, Nelson PS (Jan 2005) Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries, The Prostate, 62 (1), 1-13
  • Plymate SR, Tennant MK, Culp SH, Woodke L, Marcelli M, Colman I, Nelson PS, Carroll JM, Roberts CT Jr, Ware JL, Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tu, The Prostate, 61(3), 276-90, Nov 2004 Abstract
  • Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW (Nov 2004) Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment, The Journal of Urology, 172 (5 Pt 2), 3-5
  • Bhattacharjee M, Pritchard CC, Nelson PS, Arjas E (Nov 2004) Bayesian integrated functional analysis of microarray data., Bioinformatics, 20 (17), 2943-53
  • Nelson PS (Nov 2004) Predicting prostate cancer behavior using transcript profiles, The Journal of Urology, 172 (5 Pt 2), S28-32; discussion S
  • Clegg N, Abbott D, Ferguson C, Coleman R, Nelson PS, Characterization and comparative analyses of transcriptomes from the normal and neoplastic human prostate, The Prostate, 60(3), 227-39, Aug 2004 Abstract
  • Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR, Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9, Oncogene, 23(26), 4584-93, Jun 2004 Abstract
  • Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, Dong JT, Petros JA, Nelson PS, Marshall FF, Zhau HE, Chung LW (Mar 2004) PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer, Cancer Research, 64 (5), 1589-94
  • Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, Aebersold R, Nelson PS (Jan 2004) Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium, Cancer Research, 64 (1), 347-55
  • Nelson PS, Montgomery B, Unconventional therapy for prostate cancer: good, bad or questionable?, Nature Reviews. Cancer, 3(11), 845-58, Nov 2003 Abstract
  • Schuster JM, Longo M, Nelson PS, Differential expression of bikunin (HAI-2/PB), a proposed mediator of glioma invasion, by demethylation treatment, Journal of Neuro-oncology, 64(3), 219-25, September 2003 Abstract
  • Lin B, White JT, Utleg AG, Wang S, Ferguson C, True LD, Vessella R, Hood L, Nelson PS, Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium, Genomics, 82(3), 331-42, September 2003 Abstract
  • Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H, Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer, Cancer Cell, 4(3), 209-21, September 2003 Abstract
  • Lin DW, Nelson PS, The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma, Clin Prostate Cancer, 2(2), 119-26, Sep 2003 Abstract
  • Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL, LuCaP 35: a new model of prostate cancer progression to androgen independence, The Prostate, 55(4), 239-46, June 2003 Abstract
  • Clegg N, Ferguson C, True LD, Arnold H, Moorman A, Quinn JE, Vessella RL, Nelson PS, Molecular characterization of prostatic small-cell neuroendocrine carcinoma, The Prostate, 55(1), 55-64, April 2003 Abstract
  • Plymate SR, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Zhang Y, Oberley LW, Zhong W, Drivdahl R, Oberley TD, Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1, Oncogene, 22(7), 1024-34, February 2003 Abstract
  • Abbott DE, Pritchard C, Clegg NJ, Ferguson C, Dumpit R, Sikes RA, Nelson PS, Expressed sequence tag profiling identifies developmental and anatomic partitioning of gene expression in the mouse prostate, Genome Biology, 4(12), R79, 2003 Abstract
  • Wright ME, Eng J, Sherman J, Hockenbery DM, Nelson PS, Galitski T, Aebersold R, Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells, Genome Biology, 5(1), R4, 2003 Abstract
  • Nelson PS, Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles, Annals of the New York Academy of Sciences, 975, 232-46, December 2002 Abstract
  • Bonham MJ, Galkin A, Montgomery B, Stahl WL, Agus D, Nelson PS., Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition, Journal of the National Cancer Institute, 94(21), 1641-7, November 2002
  • Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B, The program of androgen-responsive genes in neoplastic prostate epithelium, Proceedings of the National Academy of Sciences (USA), 99(18), 11890-5, September 2002 Abstract
  • Aigner A, Renneberg H, Bojunga J, Apel J, Nelson PS, Czubayko F, Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo, Oncogene, 21(37), 5733-42, Aug 2002 Abstract
  • Kedishvili NY, Chumakova OV, Chetyrkin SV, Belyaeva OV, Lapshina EA, Lin DW, Matsumura M, Nelson PS, Evidence that the human gene for prostate short-chain dehydrogenase/reductase (PSDR1) encodes a novel retinal reductase (RalR1), Journal of Biological Chemistry, 277(32), 28909-15, Aug 2002 Abstract
  • True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA, Norwood T, Liu A, Ellis W, Lange P, Vessella R, A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49, American Journal of Pathology, 161(2), 705-15, Aug 2002 Abstract
  • Bonham M, Arnold H, Montgomery B, Nelson PS, Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma, Cancer Research, 62(14), 3920-4, July 2002 Abstract
  • Moore S, Pritchard C, Lin B, Ferguson C, Nelson PS, Isolation and characterization of the murine prostate short-chain dehydrogenase/reductase 1 (Psdr1) gene, a new member of the short-chain steroid dehydrogenase/reductase family, Gene, 293(1-2), 149-60, June 2002 Abstract
  • Moore SM, Nelson PS, Gene expression profiling of the human prostate androgen response program, Journal of Andrology, 23(2), 163-9, 2002 Abstract
  • Liu AY, Nelson PS, van den Engh G, Hood L, Human prostate epithelial cell-type cDNA libraries and prostate expression patterns, The Prostate, 50(2), 92-103, February 2002 Abstract
  • Nelson PS, Pritchard C, Abbott D, Clegg N, The human (PEDB) and mouse (mPEDB) Prostate Expression Databases, Nucleic Acids Research, 30(1), 218-20, January 2002 Abstract
  • Clegg N, Eroglu B, Ferguson C, Arnold H, Moorman A, Nelson PS, Digital expression profiles of the prostate androgen-response program, Journal of Steroid Biochemistry and Molecular Biology, 80(1), 13-23, January 2002 Abstract
  • Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL, Determining cause of death in prostate cancer: are death certificates valid?, Journal of the National Cancer Institute, 93(23), 1822-3, December 2001 Abstract
  • Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K, Characterization of hK4, a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and, Biochemistry, 40(50), 15341-8, December 2001 Abstract
  • Martin DB, Nelson PS, From genomics to proteomics: techniques and applications in cancer research, Trends in Cell Biology, 11(11), S60-5, November 2001 Abstract
  • Pritchard CC, Hsu L, Delrow J, Nelson PS, Project normal: defining normal variance in mouse gene expression, Proceedings of the National Academy of Sciences (USA), 98(23), 13266-71, November 2001 Abstract
  • Akalin A, Elmore LW, Forsythe HL, Amaker BA, McCollum ED, Nelson PS, Ware JL, Holt SE, A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression, Cancer Research, 61(12), 4791-6, 2001 Abstract
  • Grouse LH, Munson PJ, Nelson PS, Sequence databases and microarrays as tools for identifying prostate cancer biomarkers, Urology, 57(4 Suppl 1), 154-9, April 2001 Abstract
  • Kinoshita Y, Jarell AD, Flaman JM, Foltz G, Schuster J, Sopher BL, Irvin DK, Kanning K, Kornblum HI, Nelson PS, Hieter P, Morrison RS, Pescadillo, a novel cell cycle regulatory protein abnormally expressed in malignant cells, Journal of Biological Chemistry, 276(9), 6656-65, 2001 Abstract
  • Lin B, White JT, Ferguson C, Wang S, Vessella R, Bumgarner R, True LD, Hood L, Nelson PS, Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium, Cancer Research, 61(4), 1611-8, 2001 Abstract
  • Li PE, Nelson PS, Prostate cancer genomics, 2(1), 70-8, February 2001 Abstract
  • Nelson PS, Stanford JL, Ostrander EA, Prostate cancer research in the post-genome era, Epidemiologic Reviews, 23(1), 187-90, 2001 Abstract
  • Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman UH, Rittenhouse HG, Wain H, New nomenclature for the human tissue kallikrein gene family, Clinical Chemistry, 46(11), 1855-8, November 2000 Abstract
  • Schuster JM, Nelson PS, Toll receptors: an expanding role in our understanding of human disease, Journal of Leukocyte Biology, 67(6), 767-73, June 2000 Abstract
  • Nelson PS, Han D, Rochon Y, Corthals GL, Lin B, Monson A, Nguyen V, Franza BR, Plymate SR, Aebersold R, Hood L., Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics, Electrophoresis, 21, 1823-31., May 2000
  • Nelson PS, Han D, Rochon Y, Corthals GL, Lin B, Monson A, Nguyen V, Franza BR, Plymate SR, Aebersold R, Hood L, Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics, Electrophoresis, 21(9), 1823-31, May 2000 Abstract
  • Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, Sakamuro D, Nelson P, Malkowicz SB, Tomaszewski J, Prendergast GC, Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma, International Journal of Cancer, 86(2), 155-61, April 2000 Abstract
  • Lin B, White JT, Ferguson C, Bumgarner R, Friedman C, Trask B, Ellis W, Lange P, Hood L, Nelson PS, PART-1: a novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12, Cancer Research, 60(4), 858-63, February 2000 Abstract
  • Nelson PS, Clegg N, Eroglu B, Hawkins V, Bumgarner R, Smith T, Hood L, The prostate expression database \(PEDB\): status and enhancements in 2000., Nucleic Acids Research, 28(1), 212-3, 1 2000 Abstract
  • Nelson PS, Hawkins V, Schummer M, Bumgarner R, Ng WL, Ideker T, Ferguson C, Hood L, Negative selection: a method for obtaining low-abundance cDNAs using high-density cDNA clone arrays., Genetic Analysis, 15(6), 209-15, 15 Dec 1999 Abstract
  • Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L, Nelson PS, Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2., Cancer Research, 59(17), 4180-4, 1 Sep 1999 Abstract
  • Nelson PS, Gan L, Ferguson C, Moss P, Gelinas R, Hood L, Wang K, Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression., Proceedings of the National Academy of Sciences (USA), 96(6), 3114-9, 16 Mar 1999 Abstract
  • Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS, Ng WV, Schummer M, Hood L, Mulligan J, Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray, Gene, 229(1-2), 101-8, March 1999 Abstract
  • Hawkins V, Doll D, Bumgarner R, Smith T, Abajian C, Hood L, Nelson PS, PEDB: the Prostate Expression Database., Nucleic Acids Research, 27(1), 204-8, 1 Jan 1999 Abstract
  • Chaudhary PM, Ferguson C, Nguyen V, Nguyen O, Massa HF, Eby M, Jasmin A, Trask BJ, Hood L, Nelson PS, Cloning and characterization of two Toll/Interleukin-1 receptor-like genes TIL3 and TIL4: evidence for a multi-gene receptor family in humans, Blood, 91(11), 4020-7, June 1998 Abstract
  • Nelson PS, Plymate SR, Wang K, True LD, Ware JL, Gan L, Liu AY, Hood L, Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma., Cancer Research, 58(2), 232-6, 15 1998 Abstract
  • Nelson PS, Plymate SR, Wang K, True LD, Ware JL, Gan L, Liu AY, Hood L, Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma, Cancer Research, 58(2), 232-6, Jan 1998 Abstract
  • Nelson PS, Ng WL, Schummer M, True LD, Liu AY, Bumgarner RE, Ferguson C, Dimak A, Hood L, An expressed-sequence-tag database of the human prostate: sequence analysis of 1168 cDNA clones, Genomics, 47(1), 12-25, Jan 1998 Abstract
  • Schummer M, Ng W, Nelson PS, Bumgarner RE, Hood L, Inexpensive handheld device for the construction of high-density nucleic acid arrays, Biotechniques, 23(6), 1087-92, December 1997 Abstract
  • Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood L, van den Engh G, Cell-cell interaction in prostate gene regulation and cytodifferentiation., Proceedings of the National Academy of Sciences (USA), 94(20), 10705-10, 30 1997 Abstract
  • Nelson PS, Muthini S, Vierra M, Acosta L, Smith TH, Rainbow Universal CPG: a versatile solid support for oligonucleotide synthesis., Biotechniques, 22(4), 752-6, 1997 Abstract
  • Liu AY, Corey E, Vessella RL, Lange PH, True LD, Huang GM, Nelson PS, Hood L, Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer., Prostate, 30(3), 145-53, 15 1997 Abstract
  • Nelson PS, Gleason TP, Brawer MK, Chemoprevention for prostatic intraepithelial neoplasia, European Urology, 30(2), 269-78, 1996 Abstract
  • Schweinfest CW, Nelson PS, Graber MW, Demopoulos RI, Papas TS, Subtraction hybridization cDNA libraries, Methods in Molecular Biology, 37, 13-30, 1995 Abstract
  • Nelson PS, Papas TS, Schweinfest CW, Restriction endonuclease cleavage of 5-methyl-deoxycytosine hemimethylated DNA at high enzyme-to-substrate ratios, Nucleic Acids Research, 21(3), 681-6, February 1993 Abstract

Profile Details

Last Verified: 8/23/2008

COS Expertise ID #768606
Reference this profile directly: http://myprofile.cos.com/nelsonab14